Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
Nishimura N, Miyake M, Nakahama T, Miyamoto T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsumoto H, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Nishimura N, et al. Among authors: fujii t. Int J Urol. 2023 Dec;30(12):1112-1119. doi: 10.1111/iju.15283. Epub 2023 Aug 22. Int J Urol. 2023. PMID: 37605814
Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes.
Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsumoto H, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Miyake M, et al. Among authors: fujii t. BJUI Compass. 2023 Jan 13;4(3):305-313. doi: 10.1002/bco2.215. eCollection 2023 May. BJUI Compass. 2023. PMID: 37025476 Free PMC article.
Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Miyake M, et al. Among authors: fujii t. Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474. Online ahead of print. Int J Urol. 2024. PMID: 38687165
Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.
Ando F, Kashiwada T, Kuroda S, Fujii T, Takano R, Miyabe Y, Kunugi S, Sakatani T, Miyanaga A, Asatsuma-Okumura T, Hashiguchi M, Kanazawa Y, Ohashi R, Yoshida H, Seike M, Gemma A, Iwai Y. Ando F, et al. Among authors: fujii t. Front Pharmacol. 2024 May 7;15:1384731. doi: 10.3389/fphar.2024.1384731. eCollection 2024. Front Pharmacol. 2024. PMID: 38774209 Free PMC article.
Neprilysin Inhibition Promotes Skeletal Growth via the CNP/NPR-B Pathway.
Hakata T, Ueda Y, Yamashita T, Yamauchi I, Kosugi D, Sugawa T, Fujita H, Okamoto K, Fujii T, Taura D, Yasoda A, Akiyama H, Inagaki N. Hakata T, et al. Among authors: fujii t. Endocrinology. 2024 May 27;165(7):bqae058. doi: 10.1210/endocr/bqae058. Endocrinology. 2024. PMID: 38752331
6,347 results